Pharmaceutical

EMA CHMP recommends Takeda’s Hyqvia for CIDP treatment

The EMA CHMP recommended granting approval for Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy.

Dec 18, 2023 - 10:51
EMA CHMP recommends Takeda’s Hyqvia for CIDP treatment
The EMA CHMP recommended granting approval for Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy.
Read the original article

Tags:

Previous Article

CymaBay seeks FDA approval for primary biliary cholangitis therapy

Next Article

FDA backs Astellas-Pfizer’s Padcev with Keytruda for urothelial cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How did hiring in the Asia-Pacific pharma industry perform in Q2 2023

How did hiring in the Asia-Pacific pharma industry perf...

Jul 29, 2023

PTC Therapeutics gets grant for treatment of huntington...

Mar 30, 2024

NorthSea Therapeutics bags FDA rare paediatric disease tag for NASH drug

NorthSea Therapeutics bags FDA rare paediatric disease ...

Oct 17, 2023